It was founded in 1998 and focused on the research, development, and commercialization of vaccines and other biological products. Intercell AG's products were used to prevent and treat a variety of infectious diseases, including hepatitis B, Japanese encephalitis, and pneumonia. In 2012, Intercell AG merged with Vivalis SE, a French biotech company, to form
Valneva. It has been listed on the
Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire
Maryland-based
Iomai, a developer of needle-free vaccination technology. Intercell cooperates with
pharmaceutical companies like
Novartis,
Merck and
Sanofi-Aventis on vaccine production. The most important projects of Intercell are: • Vaccine against
Japanese encephalitis (approved in Europe, America and Australia) • Therapeutic vaccine against
hepatitis C (in clinical
phase II) •
Antigen identification program and
adjuvant technologies. • Vaccine Enhancement Patch to improve prevention against pandemic
influenza (in collaboration with
U.S. Department of Health and Human Services, in clinical phase II) ==References==